Company Overview
Company Type: Private Company
Website: www.medgenesis.com
Number of Employees: -
Year Founded: 2005
Total Amount Raised (CAD mm)†: 7.88
Total Rounds of Funding**:2
Latest Post-Money Valuation ($ mm) -
Latest Pre-Money Valuation ($ mm) -
† This number reflects the estimated value of the total new money raised through private placement rounds.
** This value is an estimate of the total number of funding rounds this company has received.


Business Description
MedGenesis Therapeutix Inc., a biopharmaceutical company, develops and commercializes therapeutics to provide life-enhancing treatments to patients with neurologic diseases. It provides Convection Enhanced Delivery platform, a minimally invasive technique that provides targeted and local treatment for central nervous system (CNS) conditions, such as Parkinson’s, epilepsy, brain cancer, and other diseases of the CNS. The company was founded in 2005 and is based in Victoria, Canada with locations in Mannheim, Germany; and Oakland, California.


Financial Information (Currency: CAD, in mm)
Total Revenue
-
Operating Income
-
Total Assets
-
Gross Profit
-
EBITDA
-
Total Debt
-
Net Income
-
Estimated Number of Employees
-
Net Debt
-
* Hover over data point numbers for date and source.

Key Professionals
Name
Title
Mohr, Erich 
Founder, Chairman and Chief Executive Officer
Johnson, Greg A.
President and Chief Financial Officer
Krupka-Longpre, Lara
Chief Operating Officer
Fibiger, H. Christian
Chief Scientific Officer and Director
Luz, Matthias
Chief Medical Officer

Key Board Members
Name
Title
Mohr, Erich 
Founder, Chairman and Chief Executive Officer
Fibiger, H. Christian
Chief Scientific Officer and Director
Aminoff, Michael
Member of Parkinson's Advisory Committee
Bankiewicz, Krystof
Member of CED Advisory Committee
Donnelly, Patrick K.
Director
Federoff, Howard J.
Member of Parkinson's Advisory Committee
Gillis, Steven S. 
Member of CED Advisory Committee
Kunwar, Sandeep
Member of CED Advisory Committee
Kurlan, Roger 
Member of Parkinson's Advisory Committee
Lang, Anthony E.
Member of Parkinson's Advisory Committee
Miller, Josef
Scientific Advisor of SNHL
Newport, Kenneth E.
Director


Primary Industry Classification
Pharmaceuticals


Primary Office Location
730-730 View Street | Victoria, BC | V8W 3Y7 | Canada
Phone: 250-386-3000   Fax: 250-386-3777


Company Notes
No Company Notes exist.


Strategy Notes
No Strategy Notes exist.


Current and Pending Subsidiaries / Investments
Company Name
Business Description
Geography
Primary Industry
LTM Total Rev.($mm)
LFQ Total Assets ($mm)
LFQ Total Debt ($mm)
Amgen Inc., GDNF License
As of January 12, 2010, GDNF license of Amgen Inc. was acquired by MedGenesis Therapeutix Inc. GDNF license of Amgen Inc. is a license for the usage of Glial cell-derived neurotrophic factor (GDNF), a protein used for protecting and promoting the survival of dopamine producing nerve cells. Amgen Inc. is based in Thousand Oaks, California.

United States and Canada
Biotechnology
-
-
-


Last 5 Transactions
Announced Date
Closed Date
Transaction Type
Role
Target
Buyer/Investors
Sellers
Size($mm)
Jan-10-2012
Jan-10-2012
Private Placement
Target
MedGenesis Therapeutix Inc.


4.91
Jan-12-2010
Jan-12-2010
Merger/Acquisition
Buyer
Amgen Inc., GDNF License
MedGenesis Therapeutix Inc.
Amgen Inc. (NasdaqGS:AMGN)
-
Nov-8-2006
Nov-8-2006
Private Placement
Target
MedGenesis Therapeutix Inc.


2.83
* denotes that the relationship is proprietary


Last 5 Key Developments
Date
Event Type
Headline
Sep-16-2014
Client Announcements
MedGenesis Therapeutix Inc. Enters into Agreement with Pfizer Inc. for Potential Treatments for Parkinson's Disease
Jan-14-2014
Company Conference Presentations
MedGenesis Therapeutix Inc. Presents at Biotech Showcase 2014, Jan-14-2014 08:00 AM
Mar-05-2013
Company Conference Presentations
MedGenesis Therapeutix Inc. Presents at Sachs Associates Ltd.'s 6th Annual European Life Sciences CEO Forum, Mar-05-2013 03:30 PM
Oct-24-2012
Company Conference Presentations
MedGenesis Therapeutix Inc. Presents at BIO Convention in China, Oct-24-2012
May-21-2012
Company Conference Presentations
MedGenesis Therapeutix Inc. Presents at Science, Partner, and Investment Forum 2012, May-21-2012 through May-22-2012


Last 10 Investment Research Documents
Contributor
Analyst
Date/Time
Company
Headline
Type
Pages
GlobalData

Sep 26, 2023 01:53 AM
MedGenesis Therapeutix Inc.
MedGenesis Therapeutix Inc
Reports
14
GlobalData

Jun 23, 2023 02:59 AM
MedGenesis Therapeutix Inc.
MedGenesis Therapeutix Inc
Reports
14
GlobalData

Mar 23, 2023 02:44 AM
MedGenesis Therapeutix Inc.
MedGenesis Therapeutix Inc
Reports
14
GlobalData

Dec 27, 2022 01:23 AM
MedGenesis Therapeutix Inc.
MedGenesis Therapeutix Inc
Reports
14
GlobalData

Sep 30, 2022 02:13 AM
MedGenesis Therapeutix Inc.
MedGenesis Therapeutix Inc
Reports
14
GlobalData

Jun 24, 2022 02:11 AM
MedGenesis Therapeutix Inc.
MedGenesis Therapeutix Inc
Reports
14
GlobalData

Mar 24, 2022 03:06 AM
MedGenesis Therapeutix Inc.
MedGenesis Therapeutix Inc
Reports
14
GlobalData

Dec 21, 2021 02:25 AM
MedGenesis Therapeutix Inc.
MedGenesis Therapeutix Inc
Reports
13
GlobalData

Sep 20, 2021 01:26 PM
MedGenesis Therapeutix Inc.
MedGenesis Therapeutix Inc
Reports
10
GlobalData

Jun 21, 2021 08:50 PM
MedGenesis Therapeutix Inc.
MedGenesis Therapeutix Inc
Reports
10


S&P Global Ratings Credit Ratings
No S&P Global Ratings Credit Ratings data available. 


News Headlines
No News is currently available for the selected sources.


Company Coverage
This company is not on any Coverage List.

Key Board Members Details
Name
Title
Phone
Fax
Email
Mohr, Erich 
Founder, Chairman and Chief Executive Officer
250-386-3000
250-386-3777
ErichMohr@medgenesis.com
Fibiger, H. Christian
Chief Scientific Officer and Director
250-386-3000
250-386-3777

Aminoff, Michael
Member of Parkinson's Advisory Committee
250-386-3000
250-386-3777
-
Bankiewicz, Krystof
Member of CED Advisory Committee
250-386-3000
250-386-3777
-
Donnelly, Patrick K.
Director
250-386-3000
250-386-3777
pdonnelly@lindenllc.com
Federoff, Howard J.
Member of Parkinson's Advisory Committee
250-386-3000
250-386-3777

Gillis, Steven S. 
Member of CED Advisory Committee
250-386-3000
250-386-3777
sgillis@archventure.com
Kunwar, Sandeep
Member of CED Advisory Committee
250-386-3000
250-386-3777
-
Kurlan, Roger 
Member of Parkinson's Advisory Committee
250-386-3000
250-386-3777

Lang, Anthony E.
Member of Parkinson's Advisory Committee
250-386-3000
250-386-3777
-
Miller, Josef
Scientific Advisor of SNHL
250-386-3000
250-386-3777
-
Newport, Kenneth E.
Director
250-386-3000
250-386-3777

* denotes that the relationship is proprietary

Key Executives and Professionals Details
Name
Title
Phone
Fax
Email
Mohr, Erich 
Founder, Chairman and Chief Executive Officer
250-386-3000
250-386-3777
ErichMohr@medgenesis.com
Johnson, Greg A.
President and Chief Financial Officer
250-386-3000
250-386-3777

Krupka-Longpre, Lara
Chief Operating Officer
250-386-3000
250-386-3777
-
Fibiger, H. Christian
Chief Scientific Officer and Director
250-386-3000
250-386-3777

Luz, Matthias
Chief Medical Officer
250-386-3000
250-386-3777
-
* denotes that the relationship is proprietary

S&P Credit Ratings and Research provided by 
No content (including ratings, credit-related analyses and data, valuations, model, software or other application or output therefrom) or any part thereof (Content) may be modified, reverse engineered, reproduced or distributed in any form by any means, or stored in a database or retrieval system, without the prior written permission of S&P Global Market Intelligence or its affiliates (collectively, S&P Global). The Content shall not be used for any unlawful or unauthorized purposes. S&P Global and any third-party providers, as well as their directors, officers, shareholders, employees or agents (collectively S&P Global Parties) do not guarantee the accuracy, completeness, timeliness or availability of the Content. S&P Global Parties are not responsible for any errors or omissions (negligent or otherwise), regardless of the cause, for the results obtained from the use of the Content, or for the security or maintenance of any data input by the user. The Content is provided on an "as is" basis. S&P GLOBAL PARTIES DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING, BUT NOT LIMITED TO, ANY WARRANTIES OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE OR USE, FREEDOM FROM BUGS, SOFTWARE ERRORS OR DEFECTS, THAT THE CONTENT’S FUNCTIONING WILL BE UNINTERRUPTED OR THAT THE CONTENT WILL OPERATE WITH ANY SOFTWARE OR HARDWARE CONFIGURATION. In no event shall S&P Global Parties be liable to any party for any direct, indirect, incidental, exemplary, compensatory, punitive, special or consequential damages, costs, expenses, legal fees, or losses (including, without limitation, lost income or lost profits and opportunity costs or losses caused by negligence) in connection with any use of the Content even if advised of the possibility of such damages.

Credit-related and other analyses, including ratings, and statements in the Content are statements of opinion as of the date they are expressed and not statements of fact. S&P Global Market Intelligence’s opinions, analyses and rating acknowledgment decisions (described below) are not recommendations to purchase, hold, or sell any securities or to make any investment decisions, and do not address the suitability of any security. S&P Global Market Intelligence assumes no obligation to update the Content following publication in any form or format. The Content should not be relied on and is not a substitute for the skill, judgment and experience of the user, its management, employees, advisors and/or clients when making investment and other business decisions. S&P Global Market Intelligence does not act as a fiduciary or an investment advisor except where registered as such. While S&P Global Market Intelligence has obtained information from sources it believes to be reliable, S&P Global Market Intelligence does not perform an audit and undertakes no duty of due diligence or independent verification of any information it receives.

S&P Global keeps certain activities of its divisions separate from each other in order to preserve the independence and objectivity of their respective activities. As a result, certain divisions of S&P Global may have information that is not available to other S&P Global divisions. S&P Global has established policies and procedures to maintain the confidentiality of certain non-public information received in connection with each analytical process.

S&P Global Ratings does not contribute to or participate in the creation of credit scores generated by S&P Global Market Intelligence. Lowercase nomenclature is used to differentiate S&P Global Market Intelligence PD credit model scores from the credit ratings issued by S&P Global Ratings.

S&P Global may receive compensation for its ratings and certain analyses, normally from issuers or underwriters of securities or from obligors. S&P Global reserves the right to disseminate its opinions and analyses. S&P Global's public ratings and analyses are made available on its Web sites, www.standardandpoors.com (free of charge), and www.capitaliq.com (subscription), and may be distributed through other means, including via S&P Global publications and third-party redistributors. Additional information about our ratings fees is available at www.standardandpoors.com/usratingsfees.
Regulatory News Service data provided by 
